Computed Drug–Indication Atlas logo
MBRS Bio Terminal
Dashboard • account required (locked) • Email sign-in required
Query MBRS Bio Functions
Interaction
Find biology-vs-expectation gaps and catalyst risk.
How should this user interact with the data?
Choose a mode. Switching later keeps the open tabs from the other mode intact.
Search assets, companies, indications, or type a BIO function…
Low
High
C
H
I
Asset / Indication
Headline
MBRS
Bio
Rank
Compass
Combo
Status
C
H
I
AJ1-11095 1171 → Post Polycythaemia Vera Myelofibrosis
Open · Historical graphs · Insight
UNFAVORABLE
0.42
0.50
0.50
3 / 6
0.24
1.00
C
H
I
AJ1-11095 438 → Polycythemia Vera
Open · Historical graphs · Insight
UNFAVORABLE
0.42
0.51
0.51
9 / 9
0.20
0.91
C
H
I
Fulvestrant → Breast Cancer
Open · Historical graphs · Insight
UNFAVORABLE
0.61
0.64
0.64
2 / 14
0.58
0.67
C
H
I
NVP-LDE225 → Idiopathic Myelofibrosis
Open · Historical graphs · Insight
UNFAVORABLE
0.53
0.56
0.56
5 / 15
0.49
0.71
Access MBRS Bio Terminal

Biology determines asset-indication differentiation, mispricing and landscape shifts. MBRS computes & predicts these signals. View Biotech and Pharma asset risk through the lens of Biology.

Entry
Email sign-in is required to access MBRS. New accounts enter the free dashboard, while full access to expansive drug–indication risk profiles requires subscription.
Request full database + custom features
By continuing, you agree to the Terms of Use.

MBRS Bio Terminal is a biotech asset analysis platform that evaluates drug development risk using biological signals. It helps investors, pharma business development teams, and analysts identify clinical failure risk, asset–indication differentiation, and mispriced opportunities across the therapeutic landscape.

© 2026 MBRS Bio Terminal. All rights reserved.
Biotech Asset AnalysisWhy Drugs Fail